Studies at Mayo Clinic show that oral administration of a monoclonal microbial suppresses multiple sclerosis and rheumatoid arthritis in animal models through modulation of systemic immune responses.
In the published studies, the monoclonal microbial, an anaerobic commensal microbe isolated from a human biopsy sample, led to a decrease in activity of Th17 inflammatory cells and an increase in the activity and frequency of regulatory T-cells.
Under the terms of the agreement, Evelo has a worldwide license to the technology and patent estate developed at Mayo Clinic, including multiple issued patents covering compositions and methods of use.
The data produced at Mayo and supported by Evelo's proprietary platform technologies has enabled a rapid drug development timeline with the first product candidate entering the clinic in 2018.
Revenue that Mayo Clinic receives from the development and commercialization of monoclonal microbials will be used to support its not-for-profit mission in patient care, education, and research.
Evelo Biosciences is developing monoclonal microbials, orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut, and that are broadly applicable across many diseases including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases, and cancer.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories